MedTrace Logo

Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

NCT05013723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2024-11-07

No results posted yet for this study

Summary

Use the Intermountain real-world MAb-treatment registry and control group to prospectively evaluate PACS symptoms at least 60 days after initial COVID-19 diagnosis.

Conditions

  • Post-acute COVID-19 (PACS), or "long COVID" Syndrome

Interventions

OTHER

Surveys

Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2022-12-16
Completion
2022-12-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05013723 on ClinicalTrials.gov